Medical Prognosis Institute A-S News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.12.21	Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North (GlobeNewswire)
11.12.21	Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North (GlobeNewswire)
24.11.21	Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization (GlobeNewswire)
24.11.21	Grant of New Warrants and Resolutions on Existing Warrants (GlobeNewswire)
23.11.21	Allarity Therapeutics Publishes Interim Report for the Period January – September 2021 (GlobeNewswire)
23.11.21	Minutes of Extraordinary General Meeting held on 22 November 2021 (GlobeNewswire)
11.11.21	Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus (GlobeNewswire)
05.11.21	NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021 (GlobeNewswire)
05.11.21	U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq (GlobeNewswire)
23.09.21	Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate (GlobeNewswire)
16.09.21	Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress (GlobeNewswire)
15.09.21	Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3 (GlobeNewswire)
14.09.21	Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3 (GlobeNewswire)
31.08.21	MINUTES OF EXTRAORDINARY GENERAL MEETING 2021 (GlobeNewswire)
26.08.21	Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021 (GlobeNewswire)
23.08.21	Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq (GlobeNewswire)
23.08.21	Allarity Therapeutics Publishes Interim Report for the Period January – June 2021 (GlobeNewswire)
19.08.21	New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report (GlobeNewswire)
18.08.21	Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021 (GlobeNewswire)
16.08.21	NOTICE OF EXTRAORDINARY GENERAL MEETING (GlobeNewswire)
05.08.21	Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus (GlobeNewswire)
26.07.21	Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven (GlobeNewswire)
14.07.21	Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021 (GlobeNewswire)
05.07.21	Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP® (GlobeNewswire)
24.06.21	Last day of trading with Allarity Therapeutics A/S BTU (GlobeNewswire)
14.06.21	Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib (GlobeNewswire)
11.06.21	Allarity Therapeutics Completes Oversubscribed Rights Issue (GlobeNewswire)
09.06.21	Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic (GlobeNewswire)
28.05.21	Allarity Therapeutics Publishes Interim Report for the Period January – March 2021 (GlobeNewswire)
27.05.21	Allarity Therapeutics Publishes Prospectus Supplement (GlobeNewswire)
21.05.21	Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics (GlobeNewswire)
19.05.21	Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue (GlobeNewswire)
05.05.21	Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue (GlobeNewswire)
29.04.21	Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress (GlobeNewswire)
15.04.21	MINUTES OF ANNUAL GENERAL MEETING 2021 (GlobeNewswire)
02.04.21	Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib (GlobeNewswire)
31.03.21	Notice of Annual General Meeting (GlobeNewswire)
31.03.21	Allarity Therapeutics Publishes its Annual Report for 2020 (GlobeNewswire)
23.03.21	Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million (GlobeNewswire)
09.03.21	Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma (GlobeNewswire)
04.03.21	Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer (GlobeNewswire)
24.02.21	Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus (GlobeNewswire)
11.02.21	Allarity Therapeutics Draws Down the Fourth Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
26.01.21	Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus (GlobeNewswire)
22.01.21	Allarity Therapeutics issues new shares to Aalto Capital in connection with services rendered (GlobeNewswire)
22.12.20	Allarity Therapeutics Draws Down the Third Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)
18.12.20	2020 in Review: A Letter from Allarity’s CEO (GlobeNewswire)
14.12.20	Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses (GlobeNewswire)
30.11.20	Allarity Therapeutics Publishes Interim Report for the Period January – September 2020 (GlobeNewswire)
05.11.20	Allarity Therapeutics Draws Down the Second Tranche Under Its Convertible Note Agreement with Negma Group LTD and Park Partners GP (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Medical Prognosis Institute A-S

Aktien Top/Flop

Meistgelesene Nachrichten